Applying the open artery theory: use of predictive survival markers.

. There is also thepotential for a patent infarct-related artery to providecollaterals to another infarct zone if a subsequentinfarction occurs.In the mid 1980s, angiographic comparisonsof two thrombolytic agents, tissue plasminogenactivator and streptokinase, showed the superiorityof tissue plasminogen activator in inducing earlycoronary recanalization

[1]  H. White.  Should all occluded infarct-related arteries be opened? , 1997, European heart journal.

[2]  David P Miller,et al.  End-systolic volume index at 90 to 180 minutes into reperfusion therapy for acute myocardial infarction is a strong predictor of early and late mortality. The Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO)-I Angiographic Investigators. , 1997, Circulation.

[3]  T. Böhm,et al.  Non-invasive prediction of reperfusion and coronary artery patency by continuous ST segment monitoring in the GUSTO-I trial. , 1997, European heart journal.

[4]  F. Van de Werf,et al.  Evolution of early TIMI 2 flow after thrombolysis for acute myocardial infarction. GUSTO-1 Angiographic Investigators. , 1996, Circulation.

[5]  R. Califf,et al.  Metaanalysis of five reported studies on the relation of early coronary patency grades with mortality and outcomes after acute myocardial infarction. , 1996, The American journal of cardiology.

[6]  G I Barbash,et al.  Prognostic significance of the admission electrocardiogram in acute myocardial infarction. , 1996, Journal of the American College of Cardiology.

[7]  E. Braunwald,et al.  TIMI frame count: a quantitative method of assessing coronary artery flow. , 1996, Circulation.

[8]  H. Wellens,et al.  Development of ST-segment elevation and Q- and R- wave changes in acute myocardial infarction and the influence of thrombolytic therapy. , 1996, The American journal of cardiology.

[9]  T. Henry,et al.  Early monitoring of serum cardiac troponin I for assessment of coronary reperfusion following thrombolytic therapy. , 1996, American journal of clinical pathology.

[10]  K Wegscheider,et al.  Extent of early ST segment elevation resolution: a strong predictor of outcome in patients with acute myocardial infarction and a sensitive measure to compare thrombolytic regimens. A substudy of the International Joint Efficacy Comparison of Thrombolytics (INJECT) trial. , 1995, Journal of the American College of Cardiology.

[11]  J. Cruz,et al.  The initial electrocardiogram pattern is a strong predictor of outcome in acute myocardial infarction. , 1995, International journal of cardiology.

[12]  F. Van de Werf,et al.  Benefit of thrombolytic therapy is sustained throughout five years and is related to TIMI perfusion grade 3 but not grade 2 flow at discharge. The European Cooperative Study Group. , 1995, Circulation.

[13]  G. Lamas,et al.  Effect of infarct artery patency on prognosis after acute myocardial infarction. The Survival and Ventricular Enlargement Investigators. , 1995, Circulation.

[14]  B. Gersh,et al.  Infarct size after acute myocardial infarction measured by quantitative tomographic 99mTc sestamibi imaging predicts subsequent mortality. , 1995, Circulation.

[15]  E. Braunwald,et al.  Value of radionuclide rest and exercise left ventricular ejection fraction in assessing survival of patients after thrombolytic therapy for acute myocardial infarction: results of Thrombolysis in Myocardial Infarction (TIMI) phase II study. The TIMI Study Group. , 1995, Journal of the American College of Cardiology.

[16]  K. Lee,et al.  Significance of a coronary artery with thrombolysis in myocardial infarction grade 2 flow "patency" (outcome in the thrombolysis and angioplasty in myocardial infarction trials). Thrombolysis and Angioplasty in Myocardial Infarction Study Group. , 1995, The American journal of cardiology.

[17]  R. Califf,et al.  Link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion. Importance of early and complete infarct artery reperfusion. GUSTO-I Investigators. , 1995, Circulation.

[18]  J Col,et al.  Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction. Results from an international trial of 41,021 patients. GUSTO-I Investigators. , 1995, Circulation.

[19]  M. Casl,et al.  Serum Amyloid a Protein in Patients with Acute Myocardial Infarction , 1995, Annals of clinical biochemistry.

[20]  H. Völler,et al.  Early recurrence of ST‐segment elevation in patients with initial reperfusion during thrombolytic therapy: impact on in‐hospital reinfarction and long‐term vessel patency , 1994, Coronary Artery Disease.

[21]  A. Maggioni,et al.  A simple electrocardiographic predictor of the outcome of patients with acute myocardial infarction treated with a thrombolytic agent. A Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI-2)-Derived Analysis. , 1994, Journal of the American College of Cardiology.

[22]  K. Wegscheider,et al.  Extent of early ST segment elevation resolution: a simple but strong predictor of outcome in patients with acute myocardial infarction. , 1994, Journal of the American College of Cardiology.

[23]  H. White,et al.  Long-term prognostic importance of patency of the infarct-related coronary artery after thrombolytic therapy for acute myocardial infarction. , 1994, Circulation.

[24]  E. Braunwald,et al.  Use of composite endpoints in thrombolysis trials of acute myocardial infarction. , 1993, The American journal of cardiology.

[25]  E. Braunwald.  The open-artery theory is alive and well--again. , 1993, The New England journal of medicine.

[26]  U. Tebbe,et al.  Impact of early perfusion status of the infarct-related artery on short-term mortality after thrombolysis for acute myocardial infarction: retrospective analysis of four German multicenter studies. , 1993, Journal of the American College of Cardiology.

[27]  L. Becker,et al.  TIMI Perfusion Grade 3 but Not Grade 2 Results in Improved Outcome After Thrombolysis for Myocardial Infarction Ventriculographic, Enzymatic, Electrocardiographic Evidence From the TEAM‐3 Study , 1993, Circulation.

[28]  Frans Van de Werf,et al.  An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. , 1993, The New England journal of medicine.

[29]  B. Sobel,et al.  Questions unresolved by the Third International Study of Infarct Survival. , 1992, The American journal of cardiology.

[30]  E. Braunwald,et al.  An approach to evaluating thrombolytic therapy in acute myocardial infarction. The 'unsatisfactory outcome' end point. , 1992, Circulation.

[31]  David Hunt,et al.  ISIS-3 - A RANDOMIZED COMPARISON OF STREPTOKINASE VS TISSUE PLASMINOGEN-ACTIVATOR VS ANISTREPLASE AND OF ASPIRIN PLUS HEPARIN VS ASPIRIN ALONE AMONG 41,299 CASES OF SUSPECTED ACUTE MYOCARDIAL-INFARCTION , 1992 .

[32]  J. Anderson,et al.  Does thrombolysis in myocardial infarction (TIMI) perfusion grade 2 represent a mostly patent artery or a mostly occluded artery? Enzymatic and electrocardiographic evidence from the TEAM-2 study. Second Multicenter Thrombolysis Trial of Eminase in Acute Myocardial Infarction. , 1992, Journal of the American College of Cardiology.

[33]  H. White,et al.  Effect of intravenous streptokinase as compared with that of tissue plasminogen activator on left ventricular function after first myocardial infarction. , 1989, The New England journal of medicine.

[34]  E. Braunwald,et al.  Myocardial reperfusion, limitation of infarct size, reduction of left ventricular dysfunction, and improved survival. Should the paradigm be expanded? , 1989, Circulation.

[35]  H. White.  MECHANISM OF LATE BENEFIT IN ISIS-2 , 1988, The Lancet.

[36]  H. White,et al.  Effect of intravenous streptokinase on left ventricular function and early survival after acute myocardial infarction. , 1987, The New England journal of medicine.

[37]  R Roberts,et al.  Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. , 1987, Circulation.

[38]  R M Whitlock,et al.  Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. , 1987, Circulation.

[39]  R. W. Brower,et al.  RANDOMISED TRIAL OF INTRAVENOUS RECOMBINANT TISSUE-TYPE PLASMINOGEN ACTIVATOR VERSUS INTRAVENOUS STREPTOKINASE IN ACUTE MYOCARDIAL INFARCTION Report from the European Cooperative Study Group for Recombinant Tissue-type Plasminogen Activator , 1985, The Lancet.

[40]  H. S. Mueller,et al.  The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. , 1985, The New England journal of medicine.

[41]  P. Rentrop,et al.  Changes in left ventricular ejection fraction after intracoronary thrombolytic therapy. Results of the Registry of the European Society of Cardiology. , 1983, Circulation.

[42]  Reimer Ka,et al.  The "wavefront phenomenon" of myocardial ischemic cell death. II. Transmural progression of necrosis within the framework of ischemic bed size (myocardium at risk) and collateral flow. , 1979 .